Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for Chronic HCV
December 28, 2016 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 28, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it has received a $15 million milestone payment from Janssen Research...
Data Presented at American Society of Hematology Meeting Demonstrate Potential Advantages of Factor D Inhibition for the Treatment of Complement Alternative Pathway-Mediated Diseases
December 05, 2016 16:05 ET
|
Achillion Pharmaceuticals, Inc.
SAN DIEGO, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced novel research into complement biology that both expands the understanding of this...
Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration Phase 2b Study of JNJ-4178 in Chronic HCV
November 30, 2016 06:05 ET
|
Achillion Pharmaceuticals, Inc.
- Janssen initiates dosing of patients in OMEGA-1: Phase 2b study evaluating six- and eight-week treatment durations with JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335, for the...
Achillion Announces Upcoming Presentations of Novel Research Into Complement Biology at the 58th Annual Meeting of the American Society of Hematology
November 03, 2016 09:01 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts have been accepted for poster presentation at the...
Achillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical Programs
November 03, 2016 09:00 ET
|
Achillion Pharmaceuticals, Inc.
Janssen HCV triple combination candidate JNJ-4178 reported 100% SVR12 after 6 weeks of therapy; global phase IIB study to begin 4Q 2016Achillion’s phase I MAD study with oral factor D inhibitor...
Achillion to Present at the Credit Suisse 25th Annual Healthcare Conference
November 02, 2016 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of...
Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV
September 23, 2016 11:50 ET
|
Achillion Pharmaceuticals, Inc.
- ePoster presented today at the EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap For Cure - - Ongoing Phase 2 development focusing on triple...
Achillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV
September 09, 2016 06:15 ET
|
Achillion Pharmaceuticals, Inc.
- New data released today in abstract for upcoming EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap For Cure - - Janssen advancing triple combination...
Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop
September 06, 2016 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the presentation of two posters which detailed novel preclinical research into...
Achillion to Present at Two Upcoming Investor Conferences
September 01, 2016 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...